BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12109799)

  • 1. Irinotecan, cisplatin, and radiation in esophageal cancer.
    Ilson DH; Minsky B; Kelsen D
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):11-5. PubMed ID: 12109799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
    Ilson DH; Bains M; Kelsen DP; O'Reilly E; Karpeh M; Coit D; Rusch V; Gonen M; Wilson K; Minsky BD
    J Clin Oncol; 2003 Aug; 21(15):2926-32. PubMed ID: 12885811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan in esophageal cancer.
    Ilson DH; Minsky B
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):32-6. PubMed ID: 14569846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
    Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
    Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
    Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
    J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
    Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
    Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
    Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1430-6. PubMed ID: 19540072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
    Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):75-82. PubMed ID: 20198372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
    Ilson DH; Minsky BD; Ku GY; Rusch V; Rizk N; Shah M; Kelsen DP; Capanu M; Tang L; Campbell J; Bains M
    Cancer; 2012 Jun; 118(11):2820-7. PubMed ID: 21990000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors.
    Komaki R; Janjan NA; Ajani JA; Lynch PM; Fairweather JS; Raijman I; Blumenshein GR; Ho L; Pisters PW; Feig BW; Walsh GL; Pazdur R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):34-7. PubMed ID: 11200147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
    Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
    BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
    Ruppert BN; Watkins JM; Shirai K; Wahlquist AE; Garrett-Mayer E; Aguero EG; Sherman CA; Reed CE; Sharma AK
    Am J Clin Oncol; 2010 Aug; 33(4):346-52. PubMed ID: 19841574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
    Tomblyn MB; Goldman BH; Thomas CR; Benedetti JK; Lenz HJ; Mehta V; Beeker T; Gold PJ; Abbruzzese JL; Blanke CD;
    J Thorac Oncol; 2012 May; 7(5):906-12. PubMed ID: 22481235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer.
    Nakajima TE; Ura T; Ito Y; Kato K; Minashi K; Nihei K; Hironaka S; Boku N; Kagami Y; Muro K
    Jpn J Clin Oncol; 2009 Jan; 39(1):37-42. PubMed ID: 19103671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.
    Lee MS; Mamon HJ; Hong TS; Choi NC; Fidias PM; Kwak EL; Meyerhardt JA; Ryan DP; Bueno R; Donahue DM; Jaklitsch MT; Lanuti M; Rattner DW; Fuchs CS; Enzinger PC
    Oncologist; 2013; 18(3):281-7. PubMed ID: 23429739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.